Low-dose radiotherapy (LDR) (<50 cGy) induces enhanced cell killing in vitro via the hyper-radiation sensitivity phenomenon. Aim of this study was to evaluate the safety and efficacy of a palliative regimen combining pemetrexed and LDR (as a chemopotentiator) on patients affected by recurrent non-small-cell lung cancer (NSCLC).
Mantini, G., Valentini, V., Meduri, B., Margaritora, S., Balducci, M., Micciché, F., Nardone, L., De Rose, F., Cesario, A., Larici, A., Maggi, F., Calcagni, M., Granone, P., Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study, <<RADIOTHERAPY AND ONCOLOGY>>, 2012; 105 (2): 161-166. [doi:10.1016/j.radonc.2012.09.006] [http://hdl.handle.net/10807/39779]
Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study
Mantini, Giovanna;Valentini, Valeria;Meduri, Bruno;Margaritora, Stefano;Balducci, Marinella;Nardone, Luigia;De Rose, Fiorenza;Cesario, Alfredo;Larici, Ar;Calcagni, Ml;Granone, Pierluigi
2012
Abstract
Low-dose radiotherapy (LDR) (<50 cGy) induces enhanced cell killing in vitro via the hyper-radiation sensitivity phenomenon. Aim of this study was to evaluate the safety and efficacy of a palliative regimen combining pemetrexed and LDR (as a chemopotentiator) on patients affected by recurrent non-small-cell lung cancer (NSCLC).
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
